Huang He
黄河
Professor and Chief Physician
Hematologic malignancies, allogeneic hematopoietic stem-cell transplantation, haploidentical transplantation, and CAR-T/cellular immunotherapy for leukemia, lymphoma, and multiple myeloma.(恶性血液病、异基因造血干细胞移植、半相合移植，以及面向白血病、淋巴瘤和多发性骨髓瘤的CAR-T/细胞免疫治疗。)
1,400 Outpatient hematology consultations / year
(zy91.com)Leadership & Positions
- President and Deputy Party Secretary, The First Affiliated Hospital, Zhejiang University School of Medicine
- Director, Zhejiang University Institute of Hematology
- Academic leader, Bone Marrow Transplant Center, Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine
- Vice Chair, Expert Committee of the China Marrow Donor Program
Notable Publications
Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis.
The New England Journal of Medicine (2024) — last author
PubMed/DOIGPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial.
The Lancet Haematology (2023) — last author
PubMed/DOIGenetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study.
Cell Research (2022) — last author
PubMed/DOINon-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL.
Nature (2022) — last author
PubMed/DOIT-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT.
Blood (2014) — last author
PubMed/DOIPioneering Contributions
- Official Zhejiang University and hospital sources credit Huang He's team with building a clinical translational innovation system for novel CAR-T therapies in malignant hematologic diseases.
- Official hospital reporting credits him with creating the 'Hangzhou strategy' that sequences CD7 CAR-T therapy with haploidentical allogeneic hematopoietic stem-cell transplantation for end-stage leukemia.
- Hospital and university sources credit him with pioneering non-related donor transplantation protocols in mainland China and helping establish haploidentical transplantation as a frontline option in selected settings.
- He led development and clinical translation of multiple indigenous CAR-T approaches, including allogeneic CD7 CAR-T, GPRC5D-targeted CAR-T for myeloma, and non-viral PD1-targeted CAR-T platforms.
Sources — Huang He
- https://www.zy91.com/department/doctor/74/452—identity verification, department, title, hospital leadership role, specialty focus, research directions, awards, society roles(accessed Apr 16, 2026)
- https://www.zy91.com/content/default2/176/9837—years in practice, annual outpatient volume proxy, annual inpatient volume context, national recognition, transplantation and CAR-T pioneering claims(accessed Apr 16, 2026)
- https://www.zy91.com/content/default2/63/3445—bone marrow transplant center cumulative transplant volume, CAR-T plus haploidentical transplant strategy context, center leadership identity(accessed Apr 16, 2026)
- http://hi.zju.edu.cn/2024/1204/c16769a2999545/page.htm—official summary of award-winning CAR-T translational system, product pipeline, publication count, patents, and indigenous CAR-T commercialization milestones(accessed Apr 16, 2026)
- https://person.zju.edu.cn/huanghe—identity cross-check, ZJU title, doctoral-mentor status, and institute/bone marrow transplant leadership roles(accessed Apr 16, 2026)
- https://en.zy91.com/—official English hospital name(accessed Apr 16, 2026)
- https://pubmed.ncbi.nlm.nih.gov/38657244/—publication verification: NEJM sequential CD7 CAR-T and allo-HSCT(accessed Apr 16, 2026)
- https://pubmed.ncbi.nlm.nih.gov/36725117/—publication verification: Lancet Haematology GPRC5D CAR-T trial(accessed Apr 16, 2026)
- https://pubmed.ncbi.nlm.nih.gov/36151216/—publication verification: Cell Research allogeneic CD7 CAR-T phase I study(accessed Apr 16, 2026)
- https://pubmed.ncbi.nlm.nih.gov/36045296/—publication verification: Nature non-viral targeted CAR-T in B-NHL(accessed Apr 16, 2026)
- https://pubmed.ncbi.nlm.nih.gov/25214441/—publication verification: Blood haploidentical HSCT comparative study(accessed Apr 16, 2026)